http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jeon, Gwang Joo 한국동물자원과학회 2002 한국축산학회지 Vol.44 No.6
The efficiency of marker assisted selection(MAS) over conventional selection index based sorely on phenotypic records was studied by deterministic simulation model. Parameter combination of heritability and amount of genetic variation due to the markers included in the index was employed. For the index with own phenotypic information vs. the index with own phenotypic plus marker information, the relative efficiency of MAS over the selection with phenotypic records was about 38% high when heritability was low(0.05). However, when heritability was high(50%), the relative efficiency of MAS was vary low and almost negligible. For more practical situation of selection index which included information on own, sire and dam, MAS was less effective than when selection criteria was only on own performance.
Jeon Youngsic,Yoo Jeong Eun,Rhee Hyungjin,Kim Young-Joo,Il Kim Gwang,Chung Taek,Yoon Sarah,Shin Boram,Woo Hyun Goo,Park Young Nyun 생화학분자생물학회 2021 Experimental and molecular medicine Vol.53 No.-
The expression of estrogen receptor alpha (ERα, encoded by ESR1 ) has been shown to be associated with the prognostic outcomes of patients in various cancers; however, its prognostic and mechanistic significance in hepatocellular carcinoma (HCC) remain unclear. Here, we evaluated the expression of ERα and its association with clinicopathological features in 339 HCC patients. ERα was expressed in 9.4% (32/339) of HCCs and was related to better overall survival (OS; hazard ratio [HR] = 0.11, p = 0.009, 95% C.I. = 0.016–0.82) and disease-free survival (DFS, HR = 0.4, p = 0.013, 95% C.I. = 0.18–0.85). ERα expression was also associated with features related to more favorable prognosis, such as older age, lower serum alpha-fetoprotein level, and less microvascular invasion ( p < 0.05). In addition, to obtain mechanistic insights into the role of ERα in HCC progression, we performed integrative transcriptome data analyses, which revealed that yes-associated protein (YAP) pathway was significantly suppressed in ESR1 -expressing HCCs. By performing cell culture experiments, we validated that ERα expression enhanced YAP phosphorylation, attenuating its nuclear translocation, which in turn suppressed the downstream signaling pathways and cancer cell growth. In conclusion, we suggest that ERα expression is an indicator of more favorable prognosis in HCC and that this effect is mediated by inactivation of YAP signaling. Our results provide new clinical and pathobiological insights into ERα and YAP signaling in HCC.
( Joo Hyun Lim ),( Sang Gyun Kim ),( Ji Hyun Song ),( Jae Jin Hwang ),( Dong Ho Lee ),( Jae Pil Han ),( Su Jin Hong ),( Ji Hyun Kim ),( Seong Woo Jeon ),( Gwang Ha Kim ),( Ki-Nam Shim ),( Woon Geon Sh 대한소화기학회 2017 Gut and Liver Vol.11 No.2
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the ef-ficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regi-mens and durations, and types of peptic ulcers were ana-lyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithro-mycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duode-nal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed ef-ficacy similar to that of previously reported first/second-line therapies. (Gut Liver 2017;11:226-231)
( Joo Young Lee ),( Wan Suk Lee ),( Min Kyu Jung ),( Seong Woo Jeon ),( Chang Min Cho ),( Won Young Tak ),( Young Oh Kweon ),( Sung Kook Kim ),( Yong Hwan Choi ),( Jong Gwang Kim ),( Sang Kyun Sohn ) The Editorial Office of Gut and Liver 2007 Gut and Liver Vol.1 No.2
We report a rare case of granulocytic sarcoma infiltrating the bile duct in a patient with acute myeloid leukemia. A 23-year-old man presented with jaundice and weight loss. A peripheral blood smear revealed blast cells, and the results of an examination of bone marrow aspirate were consistent with acute myeloid leukemia. The bilirubin level increased gradually after induction chemotherapy with cytarabine. Magnetic resonance cholangiopancreatography (MRCP) revealed dilatation of the intrahepatic bile ducts and smooth tapering off at the level of the common hepatic bile duct. Endoscopic retrograde cholangiopancreatography (ERCP) also revealed diffuse narrowing of the proximal common hepatic bile duct. Obstructive jaundice resolved after endoscopic nasobiliary drainage. Remission induction chemotherapy with cytarabine and idarubicin was administered, and the patient remained complete hematological remission with normal liver function tests. (Gut and Liver 2007;1:182-185)
( Gwang Ha Kim ),( Hang Lak Lee ),( Moon Kyung Joo ),( Hong Jun Park ),( Sung Woo Jung ),( Ok-jae Lee ),( Hyungkil Kim ),( Hoon Jai Chun ),( Soo Teik Lee ),( Ji Won Kim ),( Han Ho Jeon ),( Il-kwun Chu 대한간학회 2021 Gut and Liver Vol.15 No.6
Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta<sup>Ⓡ</sup> (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta<sup>Ⓡ</sup> thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta<sup>Ⓡ</sup>, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta<sup>Ⓡ</sup>, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated. Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta<sup>Ⓡ</sup>-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta<sup>Ⓡ</sup>-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was -4.01% (95% confidence interval [CI], -13.09% to 5.06%) in the ITT analysis and -4.44% (95% CI, -13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta<sup>Ⓡ</sup>-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates. Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta<sup>Ⓡ</sup>) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis. (Gut Liver 2021;15:841-850)